Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model

Journal of Thoracic Oncology

Volumn 6, Issue 9, 2011, Pages 1578-1586

  Wu, Licun ^a   Yun, Zhihong ^a   Tagawa, Tetsuzo ^a   Rey McIntyre, Katrina ^a   Anraku, Masaki ^a   De Perrot, Marc ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Chemotherapy; Immunotherapy; Mesothelioma; Regulatory T cells (Treg); Repopulation

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PC61; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; MESOTHELIOMA; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH;

EID: 80052264183     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182208ee0     Document Type: Article

References (33)

1. Ismail-Khan R, Robinson LA, Williams CC, et al. Malignant pleural mesothelioma: Comprehensive review. Cancer Control 2006;13:255-263. (Pubitemid 44600936)
2. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997;145:211-218.
3. Bianchi C, Bianchi T. Malignant mesothelioma: Global incidence and relationship with asbestos. Ind Health 2007;45:379-387. (Pubitemid 47217199)
4. Goudar RK. Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma. Ther Clin Risk Manag 2008;4:205-211. (Pubitemid 351460944)
5. Lucchi M, Picchi A, Chella A, et al. Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: Does it change anything? Interact Cardiovasc Thorac Surg 2010;10:572-576.
6. de Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:1413-1418.
7. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;121: 2636-2644. (Pubitemid 46606305)
8. Jackman DM. Current options for systemic therapy in mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:154-158.
9. Burgin M, Gairard-Dory AC, Mennecier B, et al. First-line treatment with pemetrexed in association with cisplatin in patients with nonoperable malignant pleural mesothelioma. Rev Pneumol Clin 2009;65: 75-83.
10. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007-3013.
11. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: An important cause of treatment failure. Nat Rev Cancer 2005;5:516-525. (Pubitemid 40942828)
12. Brade AM, Tannock IF. Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: Repopulation as a cause of treatment failure? J Clin Oncol 2006;24:1020-1022. (Pubitemid 46638794)
13. Wu L, Tannock IF. Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil. Cancer Res 2003;63:2134-2138. (Pubitemid 36538617)
14. Wu L, Tannock IF. Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy. Clin Cancer Res 2005;11: 8195-8200. (Pubitemid 41698764)
15. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alo ne or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005;65:2825-2831. (Pubitemid 40490085)
16. Anraku M, Cunningham KS, Yun Z, et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2008;135:823-829. (Pubitemid 351417931)
17. Wolf AM, Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-612. (Pubitemid 36182591)
18. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-4772. (Pubitemid 32691889)
19. Meloni F, Morosini M, Solari N, et al. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 2006;67:1-12. (Pubitemid 43673918)
20. McCoy MJ, Nowak AK, Lake RA. Chemoimmunotherapy: An emerging strategy for the treatment of malignant mesothelioma. Tissue Antigens 2009;74:1-10.
21. Masaki A, Yun Z, Keshavjee S, et al. Synergistic anti-tumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma. J Immunol 2010;185:956-966.
22. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982;55:1063-1074. (Pubitemid 12142723)
23. Motoyoshi Y, Kaminoda K, Saitoh O, et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep 2006;16:141-146.
24. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-648. (Pubitemid 46348738)
25. Davis MR, Manning LS, Whitaker D, et al. Establishment of a murine model of malignant mesothelioma. Int J Cancer 1992;52:881-886. (Pubitemid 23009503)
26. + progenitor-derived dendritic cells. J Exp Med 2004;199:1503-1511. (Pubitemid 38780405)
27. Turk MJ, Guevara-Patino JA, Rizzuto GA, et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004;200:771-782. (Pubitemid 39299463)
28. Heusel JW, Wesselschmidt RL, Shresta S, et al. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 1994;76:977-987. (Pubitemid 24106379)
29. Nishimura F, Dusak JE, Eguchi J, et al. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: Critical roles of IFN-inducible protein-10. Cancer Res 2006;66:4478-4487.
30. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174: 2591-2601. (Pubitemid 40279672)
31. Cao X, Sheng F. Cai SF, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007;27:635-646. (Pubitemid 47628832)
32. Bertino P, Piccardi F, Porta C, et al. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res 2008;14:541-548. (Pubitemid 351226124)
33. Agarwala SS. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: Cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res 2010;20:1-10.